CC-671 NEW
| Price | $48 | $113 | $189 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-01 |
Product Details
| Product Name: CC-671 | CAS No.: 1618658-88-0 |
| Purity: 98.66% | Supply Ability: 10g |
| Release date: 2026/06/01 |
Product Introduction
Bioactivity
| Name | CC-671 |
| Description | CC-671 is a dual inhibitor of TTK protein kinase (IC50: 0.005 μM) and CLK2 (IC50: 0.006 μM). |
| Kinase Assay | The kinase selectivity profile of CC-671 is assessed. The screen is conducted with the concentration of CC-671 held constant at 3 μM. The TTK binding affinity is measured using the kinase binding assays. The kinase binding assays are based on the binding and displacement of a proprietary, Alexa Fluor 647-labeled, ATP-competitive kinase inhibitor scaffold[1]. |
| Animal Research | Female SCID mice are inoculated subcutaneously with 5×106 Cal-51 cells. Mice with tumours of approximately 125 mm3 are randomized and treated intravenously at various doses and schedules of CC-671 (n=8 to10/group). Tumours are measured twice a week for the duration of the study. The long and short axes of each a tumour are measured using a digital calliper in millimetres and the tumour volumes are calculated[1]. |
| In vitro | HCT-116 cell lysates treated with CC-671 at 3 μM for 1 h demonstrates that only four kinases show cellular binding of 75% or more including CLK2, CAMKK2, PIP4K22, and JNK[1]. |
| In vivo | CC-671 significantly inhibits tumor growth by 71% at doses of both 10 and 20 mg/kg on an every 3 days (q3d) dosing schedule, with no difference in efficacy between the two doses. However, it induces greater body weight loss at 20 mg/kg compared to 10 mg/kg (17% vs 5%)[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 120 mg/mL (234.12 mM), Sonication is recommended. 10% DMSO+90% Saline : < 10 mg/mL (19.51 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 10 mg/mL (19.51 mM), Solution. |
| Keywords | TTK | Inhibitor | inhibit | Cyclin dependent kinase | CLK2 | CDK | CC-671 | CC671 | CC 671 |
| Inhibitors Related | Ribociclib | Amantadine | 2-Chloropyrazine | Kojic acid | Ruxolitinib | Abemaciclib | Ibrutinib | Vidarabine | Palbociclib | Gefitinib | Sodium Oxamate | 2,4,6-Trihydroxybenzoic acid |
| Related Compound Libraries | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Anti-Breast Cancer Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Preclinical Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY